stocks logo

SWTX

SpringWorks Therapeutics Inc
$
0.000
-46.99(-100.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
2.78B
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
74.09M
EV
3.25B
EV/OCF(TTM)
--
P/S(TTM)
15.92
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
86.45M
+75.35%
-1.120
+7.69%
73.39M
+22.86%
-1.050
+45.83%
66.95M
+218.74%
-0.970
+79.63%
Estimates Revision
The market is revising Downward the revenue expectations for SpringWorks Therapeutics, Inc. (SWTX) for FY2025, with the revenue forecasts being adjusted by -2.03% over the past three months. During the same period, the stock price has changed by 1.75%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+13.77%
In Past 3 Month
Stock Price
Go Up
up Image
+1.75%
In Past 3 Month
6 Analyst Rating
up Image0
Wall Street analysts forecast SWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SWTX is 53.17 USD with a low forecast of 47.00 USD and a high forecast of 84.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
5 Hold
0 Sell
Hold
up Image0
Current: 0
sliders
Low
47.00
Averages
53.17
High
84.00
BofA
NULL -> No Rating
downgrade
$47
2025-04-25
Reason
BofA is moving to No Rating on SpringWorks Therapeutics (SWTX) given that shares are trading near the Merck KGaA (MKGAY) potential offer price of $47 per share and "no longer trading on fundamentals." A $47 per share price, while below expectations, would be a validation of the market opportunity for Gomekli and Ogsiveo, the analyst stated.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$74
2025-02-24
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$74
2025-02-21
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$74
2025-02-12
Reason
Evercore ISI Group
Cory Kasimov
Buy
Maintains
$60 → $65
2025-02-12
Reason
Wedbush
David Nierengarten
Buy
Reiterates
$77
2025-02-12
Reason

Valuation Metrics

The current forward P/E ratio for SpringWorks Therapeutics Inc (SWTX.O) is -13.72, compared to its 5-year average forward P/E of -15.93. For a more detailed relative valuation and DCF analysis to assess SpringWorks Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.93
Current PE
-13.72
Overvalued PE
-5.92
Undervalued PE
-25.94

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.90
Current EV/EBITDA
-26.02
Overvalued EV/EBITDA
-3.59
Undervalued EV/EBITDA
-20.21

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
465.91
Current PS
9.27
Overvalued PS
1426.93
Undervalued PS
-495.11

Financials

Annual
Quarterly
FY2025Q1
YoY :
+133.68%
49.09M
Total Revenue
FY2025Q1
YoY :
-14.26%
-80.54M
Operating Profit
FY2025Q1
YoY :
-4.80%
-83.19M
Net Income after Tax
FY2025Q1
YoY :
-5.93%
-1.11
EPS - Diluted
FY2025Q1
YoY :
-13.48%
-68.79M
Free Cash Flow
FY2025Q1
YoY :
-1.56%
92.81
Gross Profit Margin - %
FY2025Q1
YoY :
-59.26%
-169.47
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
25.1M
USD
12
6-9
Months
2.9M
USD
2
0-12
Months
2.8M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
243.8K
Volume
1
6-9
Months
383.1K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
981.8K
Volume
Months
6-9
5
5.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
32.5K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
16.0K
USD
Months
0-12
0
0.0
USD
Months

SWTX News & Events

Events Timeline

2025-07-22 (ET)
2025-07-22
08:30:11
Sixteen option delistings on July 22nd
select
2025-07-18 (ET)
2025-07-18
11:34:22
SpringWorks reports conditional approval of Ezmekly in EU
select
2025-05-23 (ET)
2025-05-23
08:01:18
SpringWorks Therapeutics receives positive CHMP opinion for mirdametinib
select
Sign Up For More Events

News

9.0
06-20Newsfilter
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
3.0
06-16NASDAQ.COM
Validea Detailed Fundamental Analysis - SWTX
7.0
06-15Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
Sign Up For More News

FAQ

arrow icon

What is SpringWorks Therapeutics Inc (SWTX) stock price today?

The current price of SWTX is 0 USD — it has increased 0.02 % in the last trading day.

arrow icon

What is SpringWorks Therapeutics Inc (SWTX)'s business?

arrow icon

What is the price predicton of SWTX Stock?

arrow icon

What is SpringWorks Therapeutics Inc (SWTX)'s revenue for the last quarter?

arrow icon

What is SpringWorks Therapeutics Inc (SWTX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for SpringWorks Therapeutics Inc (SWTX)'s fundamentals?

arrow icon

How many employees does SpringWorks Therapeutics Inc (SWTX). have?

arrow icon

What is SpringWorks Therapeutics Inc (SWTX) market cap?